MX2013013924A - Composicion inmunogenica. - Google Patents
Composicion inmunogenica.Info
- Publication number
- MX2013013924A MX2013013924A MX2013013924A MX2013013924A MX2013013924A MX 2013013924 A MX2013013924 A MX 2013013924A MX 2013013924 A MX2013013924 A MX 2013013924A MX 2013013924 A MX2013013924 A MX 2013013924A MX 2013013924 A MX2013013924 A MX 2013013924A
- Authority
- MX
- Mexico
- Prior art keywords
- seq
- fragment
- toxin
- relates
- immunogenic composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 12
- 101710084578 Short neurotoxin 1 Proteins 0.000 abstract 3
- 101710182223 Toxin B Proteins 0.000 abstract 3
- 101710182532 Toxin a Proteins 0.000 abstract 3
- 241000193163 Clostridioides difficile Species 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a proteínas de fusión que comprenden fragmentos de toxina A y/o toxina B de Clostridium difficile; en particular, la invención se refiere a proteínas que comprenden un primer fragmento y un segundo fragmento, en donde (v) el primer fragmento es un fragmento de dominio repetido de toxina A; (vi) el segundo fragmento es un fragmento de dominio repetido de toxina B; (vii) el primer fragmento tiene un primer extremo proximal; (viii) el segundo fragmento tiene un segundo extremo proximal; y en donde el primer fragmento y el segundo fragmento son adyacentes entre sí, y en donde el polipéptido provoca anticuerpos que neutralizan la toxina A o la toxina B, o ambas. Además, la invención se refiere a composiciones que comprenden fragmentos o variantes de SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:28 SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33 o SEQ ID NO:34 o SEQ ID NO:35.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490716P | 2011-05-27 | 2011-05-27 | |
| US201161490707P | 2011-05-27 | 2011-05-27 | |
| US201161490734P | 2011-05-27 | 2011-05-27 | |
| PCT/EP2012/059805 WO2012163817A2 (en) | 2011-05-27 | 2012-05-25 | Immunogenic composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013013924A true MX2013013924A (es) | 2013-12-16 |
| MX346200B MX346200B (es) | 2017-03-10 |
Family
ID=46168484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013013924A MX346200B (es) | 2011-05-27 | 2012-05-25 | Composicion inmunogenica. |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US9290565B2 (es) |
| EP (6) | EP2714911B1 (es) |
| JP (3) | JP2014516532A (es) |
| KR (1) | KR102014502B1 (es) |
| CN (3) | CN103732750A (es) |
| BR (2) | BR112013030396A2 (es) |
| CA (2) | CA2837393A1 (es) |
| CY (3) | CY1118599T1 (es) |
| DK (4) | DK3564378T5 (es) |
| EA (1) | EA030898B1 (es) |
| ES (4) | ES2743442T3 (es) |
| FI (1) | FI3564378T3 (es) |
| HR (4) | HRP20180339T1 (es) |
| HU (4) | HUE037126T2 (es) |
| IL (1) | IL229529B2 (es) |
| LT (4) | LT3138916T (es) |
| ME (1) | ME02600B (es) |
| MX (1) | MX346200B (es) |
| PL (4) | PL3564378T3 (es) |
| PT (4) | PT2714911T (es) |
| RS (1) | RS55605B1 (es) |
| SG (1) | SG195037A1 (es) |
| SI (4) | SI3138916T1 (es) |
| SM (2) | SMT201700110T1 (es) |
| WO (3) | WO2012163810A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201700124T1 (it) | 2010-09-03 | 2017-05-08 | Valneva Austria Gmbh | Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi |
| BR122019017005B1 (pt) | 2011-04-22 | 2022-03-29 | Wyeth Llc | Composições que se relacionam a uma toxina de clostridium difficile mutante |
| AU2012349753A1 (en) | 2011-12-08 | 2014-06-19 | Novartis Ag | Clostridium difficile toxin-based vaccine |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| SG11201503861UA (en) | 2012-12-05 | 2015-06-29 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| EP2988778A4 (en) * | 2013-04-22 | 2016-12-14 | Board Of Regents Of The Univ Of Oklahoma | CLOSTRIDIUM DIFFICILE IMPREGENT AND METHOD OF USE |
| HK1250167A1 (zh) | 2015-02-19 | 2018-11-30 | 免疫生物进化公司 | 艰难梭菌毒素a和/或b抗原和表位抗体及其药学用途 |
| CA3102353A1 (en) * | 2018-06-19 | 2019-12-26 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
| US20250213667A1 (en) | 2022-06-01 | 2025-07-03 | Valneva Austria Gmbh | Clostridium difficile vaccine |
| WO2024160901A1 (en) | 2023-02-02 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| JP2002514886A (ja) | 1994-10-24 | 2002-05-21 | プロメガ コーポレーション | クロストリジウム・ディフィシル疾患の治療及び予防のためのワクチン及び抗トキシン |
| NZ312502A (en) * | 1995-07-07 | 1999-03-29 | Oravax Inc | Clostridium difficile toxins as mucosal adjuvants |
| WO2000061762A1 (en) * | 1999-04-09 | 2000-10-19 | Techlab, Inc. | RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE) |
| JP2002541808A (ja) | 1999-04-09 | 2002-12-10 | テクラブ， インコーポレイテッド | ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア |
| WO2001073030A2 (en) | 2000-03-28 | 2001-10-04 | Diadexus, Inc. | Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer |
| WO2010017383A1 (en) * | 2008-08-06 | 2010-02-11 | Emergent Product Development Uk Limited | Vaccines against clostridium difficile and methods of use |
| WO2011060431A2 (en) * | 2009-11-16 | 2011-05-19 | University Of Maryland Baltimore | Multivalent live vector vaccine against clostridium difficile-associated disease |
| SMT201700124T1 (it) * | 2010-09-03 | 2017-05-08 | Valneva Austria Gmbh | Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi |
| GB201016742D0 (en) * | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
-
2012
- 2012-05-25 EP EP12726374.7A patent/EP2714911B1/en not_active Revoked
- 2012-05-25 HR HRP20180339TT patent/HRP20180339T1/hr unknown
- 2012-05-25 LT LTEP16193340.3T patent/LT3138916T/lt unknown
- 2012-05-25 LT LTEP12726374.7T patent/LT2714911T/lt unknown
- 2012-05-25 EP EP19179871.9A patent/EP3564378B1/en not_active Revoked
- 2012-05-25 JP JP2014511895A patent/JP2014516532A/ja active Pending
- 2012-05-25 LT LTEP19179871.9T patent/LT3564378T/lt unknown
- 2012-05-25 US US14/122,690 patent/US9290565B2/en not_active Expired - Fee Related
- 2012-05-25 PT PT127263747T patent/PT2714911T/pt unknown
- 2012-05-25 PT PT16193340T patent/PT3138916T/pt unknown
- 2012-05-25 CN CN201280037466.8A patent/CN103732750A/zh active Pending
- 2012-05-25 SI SI201231642T patent/SI3138916T1/sl unknown
- 2012-05-25 ES ES16193340T patent/ES2743442T3/es active Active
- 2012-05-25 BR BR112013030396A patent/BR112013030396A2/pt not_active IP Right Cessation
- 2012-05-25 US US14/122,345 patent/US9409974B2/en active Active
- 2012-05-25 DK DK19179871.9T patent/DK3564378T5/da active
- 2012-05-25 CA CA2837393A patent/CA2837393A1/en not_active Abandoned
- 2012-05-25 SI SI201231247T patent/SI2714910T1/en unknown
- 2012-05-25 DK DK12724950.6T patent/DK2714910T3/en active
- 2012-05-25 HR HRP20231749TT patent/HRP20231749T1/hr unknown
- 2012-05-25 LT LTEP12724950.6T patent/LT2714910T/lt unknown
- 2012-05-25 HR HRP20170094TT patent/HRP20170094T1/hr unknown
- 2012-05-25 HU HUE12724950A patent/HUE037126T2/hu unknown
- 2012-05-25 HU HUE12726374A patent/HUE030823T2/en unknown
- 2012-05-25 PL PL19179871.9T patent/PL3564378T3/pl unknown
- 2012-05-25 ME MEP-2017-26A patent/ME02600B/me unknown
- 2012-05-25 HU HUE19179871A patent/HUE064492T2/hu unknown
- 2012-05-25 CA CA2837395A patent/CA2837395C/en active Active
- 2012-05-25 DK DK16193340.3T patent/DK3138916T3/da active
- 2012-05-25 SI SI201232050T patent/SI3564378T1/sl unknown
- 2012-05-25 DK DK12726374.7T patent/DK2714911T3/en active
- 2012-05-25 PT PT127249506T patent/PT2714910T/pt unknown
- 2012-05-25 ES ES12726374.7T patent/ES2615737T3/es active Active
- 2012-05-25 PL PL12726374T patent/PL2714911T3/pl unknown
- 2012-05-25 CN CN201280037472.3A patent/CN103717742B/zh active Active
- 2012-05-25 RS RS20170051A patent/RS55605B1/sr unknown
- 2012-05-25 MX MX2013013924A patent/MX346200B/es active IP Right Grant
- 2012-05-25 PT PT191798719T patent/PT3564378T/pt unknown
- 2012-05-25 PL PL16193340T patent/PL3138916T3/pl unknown
- 2012-05-25 KR KR1020137034795A patent/KR102014502B1/ko active Active
- 2012-05-25 EP EP18150735.1A patent/EP3327126A1/en not_active Withdrawn
- 2012-05-25 EA EA201391548A patent/EA030898B1/ru not_active IP Right Cessation
- 2012-05-25 EP EP23205566.5A patent/EP4296361A3/en active Pending
- 2012-05-25 FI FIEP19179871.9T patent/FI3564378T3/fi active
- 2012-05-25 BR BR112013030395-6A patent/BR112013030395B1/pt active IP Right Grant
- 2012-05-25 HU HUE16193340 patent/HUE044772T2/hu unknown
- 2012-05-25 SI SI201230868A patent/SI2714911T1/sl unknown
- 2012-05-25 ES ES12724950.6T patent/ES2660468T3/es active Active
- 2012-05-25 EP EP12724950.6A patent/EP2714910B1/en active Active
- 2012-05-25 WO PCT/EP2012/059792 patent/WO2012163810A1/en not_active Ceased
- 2012-05-25 ES ES19179871T patent/ES2968455T3/es active Active
- 2012-05-25 SM SM20170110T patent/SMT201700110T1/it unknown
- 2012-05-25 SG SG2013085386A patent/SG195037A1/en unknown
- 2012-05-25 PL PL12724950T patent/PL2714910T3/pl unknown
- 2012-05-25 EP EP16193340.3A patent/EP3138916B1/en not_active Revoked
- 2012-05-25 WO PCT/EP2012/059793 patent/WO2012163811A1/en not_active Ceased
- 2012-05-25 JP JP2014511899A patent/JP5952390B2/ja active Active
- 2012-05-25 CN CN201710239709.0A patent/CN107098977A/zh active Pending
- 2012-05-25 WO PCT/EP2012/059805 patent/WO2012163817A2/en not_active Ceased
-
2013
- 2013-11-21 IL IL229529A patent/IL229529B2/en unknown
-
2016
- 2016-02-11 US US15/041,924 patent/US9644024B2/en not_active Expired - Fee Related
- 2016-06-09 JP JP2016114910A patent/JP2017012160A/ja active Pending
- 2016-06-28 US US15/194,937 patent/US10093722B2/en active Active
-
2017
- 2017-02-03 CY CY20171100158T patent/CY1118599T1/el unknown
- 2017-02-16 SM SM201700110T patent/SMT201700110B/it unknown
- 2017-03-21 US US15/464,454 patent/US10377816B2/en active Active
-
2018
- 2018-02-15 CY CY20181100188T patent/CY1119916T1/el unknown
-
2019
- 2019-07-17 HR HRP20191291TT patent/HRP20191291T1/hr unknown
- 2019-08-27 CY CY20191100909T patent/CY1121936T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX346200B (es) | Composicion inmunogenica. | |
| PH12013502178B1 (en) | Compositions relating to a mutant clostridium difficile toxin and methods thereof | |
| TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
| IN2012DN02604A (es) | ||
| NZ585777A (en) | Compositions and methods of enhancing immune responses to eimeria | |
| BR112015014727A2 (pt) | composição imunogênica, uso de uma composição imunogênica, e, método para prevenir ou tratar a doença c.difficile | |
| MX351414B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
| WO2013055888A3 (en) | Recombinant human naglu protein and uses thereof | |
| MX2011012039A (es) | Anticuerpos bloqueadores anti-dkk-1 y sus usos. | |
| WO2013016468A3 (en) | Compositions and methods for improving potency and breadth or hiv antibodies | |
| MX379863B (es) | Composiciones y metodos relacionados con una toxina mutante de clostridium difficile | |
| WO2009137778A3 (en) | Methods and compositions for genetically engineering clostridia species | |
| MX364623B (es) | Fragmentos mutantes de ospa y métodos y usos relacionados con estos. | |
| NZ721015A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| NZ703546A (en) | Composition comprising a mixture of cd95-fc isoforms | |
| NZ757950A (en) | Lactase enzymes with improved properties | |
| WO2010011952A3 (en) | Flip death effector domain derived peptides for inducing autophagy | |
| HRP20220064T1 (hr) | Zglobno modificirani fragmenti protutijela i postupci za pripravu | |
| MX365560B (es) | Proteinas quimericas basadas en cyaa que comprenden un polipeptido heterologo y sus usos en la induccion de respuestas inmunes. | |
| WO2009118660A3 (en) | Adam-15 antibodies and immunogenic peptides | |
| MY180681A (en) | Compositions and methods for treatment of aortic fibrosis | |
| AU2016203241A1 (en) | Immunogenic composition | |
| CA2868057C (en) | Epsilon toxin epitopes from clostridium perfringens with reduced toxicity | |
| WO2023099711A3 (en) | Single domain antibodies for prevention of clostridium difficile infection | |
| MX2009011851A (es) | Plasmidos de dna que tienen expresion y estabilidad mejoradas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |